KalVista shares up 10.95% intraday as Needham maintains Buy rating at $28.

KalVista Pharmaceuticals (KALV) surged 10.95% intraday after Needham reiterated its Buy rating with a $28 price target, maintaining confidence in the company’s prospects. The analyst update, which affirmed prior recommendations, likely reinforced investor optimism amid ongoing market volatility. The stock’s sharp intraday gain aligns with the positive rating, suggesting renewed institutional or retail buying interest following the reaffirmation of a long-term growth outlook. No contradictory or unrelated news was reported in the provided data.